20-F: Immutep Limited Reports Financial Results and Provides Business Update in Annual 20-F Filing

Immutep Limited's 20-F filing details the company's financial performance, ongoing clinical trials, and intellectual property, highlighting a net loss for fiscal year 2024 and continued investment in research and development.

Summary

• Immutep Limited's 20-F filing reveals a net loss of A$42.7 million for the fiscal year ended June 30, 2024, compared to a loss of A$39.9 million in the previous year.
• The company is focused on developing immunotherapeutic products, particularly those related to LAG-3, for cancer and autoimmune diseases.
• Key programs include eftilagimod alpha (efti), IMP701, IMP731, IMP761, and a small molecule anti-LAG-3 program.
• Immutep has collaboration agreements with Merck & Co., Merck KGaA, and Pfizer to evaluate efti in combination with other therapies.
• The company anticipates increased expenses related to clinical trials, particularly for efti, and may require additional funding.
• Immutep relies on third-party manufacturers and suppliers, which poses risks to the supply chain and manufacturing process.
• The company is subject to extensive regulations by regulatory authorities in the United States, the United Kingdom, the European Union, and Australia.
• Immutep's stock price is volatile and could decline significantly, affecting investors' interest in the company's securities.
• The company is subject to the auditor attestation requirement under the Sarbanes-Oxley Act, imposing significant costs and administrative burden.
• The company is exposed to differing legal and tax laws in multiple jurisdictions, including complex transfer pricing rules in Australia.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative information. While there are promising clinical trial results and collaborations, the company is still operating at a loss and faces several risks. The sentiment is neutral to slightly positive.

Positives

• Immutep has collaboration agreements with major pharmaceutical companies like Merck & Co., Merck KGaA, and Pfizer.
• The FDA granted Fast Track designation to eftilagimod alpha (efti or IMP321) in combination with pembrolizumab for the 1st line treatment of Stage IIIB/IV NSCLC patients expressing PD-L1 Tumor Proportion Score > 1%.

Negatives

• Immutep Limited reported a net loss of A$42.7 million for the fiscal year ended June 30, 2024.
• The company is subject to the auditor attestation requirement under Section 404 of the Sarbanes-Oxley Act of 2002.
• The company is exposed to differing legal and tax laws in multiple jurisdictions, including complex transfer pricing rules in Australia.

Risks

• The success of product candidates is uncertain, and the company has a history of operating losses.
• The company is dependent on the future success of its product candidates and has no source of consistent material revenue.
• The company may be unable to raise sufficient capital, which could have a material impact on its research and development programs.
• The company may find it difficult to enroll patients in its clinical trials, which could delay or prevent completion of clinical trials.
• Positive results from preclinical studies are not necessarily predictive of the results of clinical trials.
• Ongoing and future clinical trials may not show sufficient safety or efficacy to obtain regulatory approvals.
• The company has limited manufacturing experience and is dependent on third parties for cost-effective manufacture.
• The company depends on collaborations and strategic alliances with third parties, which may be terminated for reasons beyond its control.
• The company may be exposed to product liability claims which could harm its business.
• The outbreak of war, a pandemic, or macroeconomic factors could adversely impact the company's business.
• The company's internal computer systems may fail or suffer security breaches, which could result in a material disruption of its product development programs.
• The company's success depends on its ability to protect its intellectual property and proprietary technology.
• The company's stock price is volatile and could decline significantly.
• The company may be or become a passive foreign investment company (PFIC), which would subject its U.S. shareholders to adverse tax rules.
• Currency fluctuations may adversely affect the price of the ADSs relative to the price of the company's ordinary shares.

Future Outlook

Immutep anticipates that its current cash and cash equivalents will be sufficient to fund its operations at least until the end of calendar year 2026 and expects to incur substantial and increasing losses for the next several years as it expands its research and development activities and moves its product candidates into later stages of development.

Management Comments

• We are eager to build upon the meaningful impact that immunotherapy has brought to patients with NSCLC, one of the largest cancer indications globally, and look for TACTI-004 to confirm the clinical benefits that have been achieved with efti in combination with KEYTRUDA. We are thankful for this significant commitment from MSD, stated Marc Voigt, CEO of Immutep.
• KEYTRUDA has revolutionized the treatment landscape in NSCLC and our confidence in eftis ability to build upon its positive impact on patient outcomes, and potentially expand the number of responding patients, stems from the compelling data in our TACTI-002 and INSIGHT-003 trials. We are excited to confirm the differentiated efficacy and safety that we have seen to date in NSCLC via eftis first pivotal Phase III study and TACTI-004s robust randomized, double-blind trial design, added Christian Mueller, Immuteps SVP, Regulatory and Strategy.

Industry Context

The document highlights the competitive landscape of the biopharmaceutical industry, particularly in immuno-oncology, where numerous companies are developing treatments for similar target disease indications. The document also notes the increasing efforts of governments and insurance companies to contain healthcare costs, which may affect the company's future revenues and profitability.

Comparison to Industry Standards

• The document compares the initial median Overall Survival (mOS) of 25.0 months achieved in 1st line NSCLC patients with PD-L1 TPS > 1% in the TACTI-002 trial to reported rates from registration trials of anti-PD-1 monotherapy (16.4-month mOS) and combinations of anti-PD-1 with chemotherapy (15.8 to 23.3-month mOS) or with anti-CTLA-4 (17.1-month mOS).
• The document compares the results from the chemo-free combination of efti plus pembrolizumab in patients with a PD-L1 CPS > 1 in the TACTI-002 trial to reported results from a registrational trial of anti-PD-1 monotherapy in the same patient population, which showed a 17.3% ORR, mOS of 8.7 months, 12-month OS rate of 40%, a CR rate of 2%, and mDoR of 18.4 months.
• The document compares the strong ORR observed in the INSIGHT-003 trial to results from an independent registrational trial of anti-PD-1 and doublet chemotherapy, which reported a response rate of 40.8% in a similar patient population.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, clinical trial results, and ability to secure funding.
• Employees are affected by the company's ability to retain and motivate skilled personnel.
• Patients are impacted by the development of new treatment options for cancer and autoimmune diseases.
• Suppliers and creditors are affected by the company's ability to meet its financial obligations.

Next Steps

• Immutep is preparing to commence TACTI-004, its Phase III trial of efti in combination with an anti-PD-1 therapy in 1st line NSCLC.
• The Company will continue to progress the development of IMP761, Immuteps proprietary product candidate and the worlds first LAG-3 agonist for autoimmune diseases.

Key Dates

Keywords

Immutep, eftilagimod alpha, LAG-3, immunotherapy, clinical trials, financial results, 20-F filing, risk factors, intellectual property, regulatory approvals